Last deal

$40M

Amount

Post-IPO Equity

Stage

10.04.2024

Date

3

all rounds

$266.5M

Total amount

date founded

Financing round

General

About Company
Leap Therapeutics develops cancer therapies by inhibiting tumor-promoting pathways and activating the immune system.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2011

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's clinical stage program focuses on DKN-01, a monoclonal antibody that targets a protein called DKK1, which promotes tumor growth and suppresses the immune system. Leap Therapeutics is conducting multiple clinical trials to study DKN-01 in various types of cancer, including esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Additionally, the company is involved in other clinical studies, such as P100, P102, P204, and P205. Leap Therapeutics is a clinical-stage biopharmaceutical company at the forefront of cancer research, acquiring and developing innovative therapeutics. For more information, visit their website or public filings with the SEC.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Inspyr Therapeutics

Inspyr Therapeutics

Inspyr Therapeutics develops targeted cancer therapeutics for various types of tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Antonio, TX, USA

total rounds

11

total raised

$23.3M
G1 Therapeutics

G1 Therapeutics

G1 Therapeutics is a clinical-stage company developing novel cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Durham, NC, USA

total rounds

10

total raised

$697.37M
Samus Therapeutics

Samus Therapeutics

Samus Therapeutics is developing novel therapeutics targeting the epichaperome.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Danvers, MA 01923, USA
Sapience Therapeutics

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotech company developing novel therapeutics for cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Scarsdale, NY 10583, USA

total rounds

7

total raised

$73.51M

Financials

Funding Rounds
10
3

Number of Funding Rounds

$266.5M

Money Raised

Their latest funding was raised on 10.04.2024. Their latest investor Gilead Sciences. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
10.04.2024
5
$40M
22.09.2021
$90M
18.06.2020
$45M
Co-Investors
Investors
10
2

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
No
Post-IPO Equity
No
Post-IPO Equity
No
Post-IPO Equity
Gilead Sciences

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Biopharma

Location

Foster City, CA, USA

total rounds

4

total raised

$4.41B

count Of Investments

62

count Of Exists

1

683 CAPITAL

683 CAPITAL MANAGEMENT is a hedge fund.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance

count Of Investments

7
Samsara BioCapital

Samsara BioCapital

Samsara BioCapital is a Palo Alto-based venture capital firm specializing in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Palo Alto, CA, USA

count Of Investments

123

count Of Exists

1
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
Flame Biosciences acquired by Leap Therapeutics

Flame Biosciences acquired by Leap Therapeutics

acquirer

Leap Therapeutics
Leap Therapeutics

date

17.01.2023
Flame Biosciences

Flame Biosciences

Flame Biosciences develops value-added medicines in the emerging area of inflammasome science.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

New York, NY, USA

total rounds

1

total raised

$100M
MacroCure acquired by Leap Therapeutics

MacroCure acquired by Leap Therapeutics

acquirer

Leap Therapeutics
Leap Therapeutics

date

29.08.2016

type

Acquisition
MacroCure

MacroCure

MacroCure is a biopharmaceutical company that develops and commercializes advanced cell therapy products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

E-Commerce, Biotechnology, Health Care

Location

Petah Tikva, Israel

total rounds

2

total raised

$48M

People

Founders
1
Douglas E. Onsi
Douglas E. Onsi

Douglas E. Onsi

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

current job

Leap Therapeutics
Leap Therapeutics

Douglas E. Onsi

Employee Profiles
8

Lianna Cohen

Senior clinical data manager

Jonathan Miller

Associate director, financial planning and analysis

Gus Lawlor

Gus Lawlor

Chief Operating Officer

Cyndi Sirard

Cyndi Sirard

Chief Medical Officer

Chris Mirabelli

President & CEO

Douglas E. Onsi

Douglas E. Onsi

Chief Financial Officer

Mark O'Mahony

Mark O'Mahony

Chief Manufacturing Officer

Activity

Recent News
7
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month